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Abstract
Background: Clinical trials on the prophylactic effect of propranolol and metoprolol for migraine show that starting this
medication leads to a decrease in the use of attack medication of 0.9–8.9 doses per month. However, studies in daily
practice are lacking.
Methods: We compared the number of triptans prescribed in the six months before and the six months after the start of
propranolol/metoprolol in a Dutch national representative primary care cohort.
Results: Of the 168 triptan-using patients who started with propranolol or metoprolol, the number of triptans prescribed
before starting was 4.6 doses per month. The number of triptans prescribed six months before compared with six
months after starting propranolol/metoprolol decreased with 1.0 dose per month (Wilcoxon rank test; p¼ 0.000).
Conclusion: In this primary care population, although the number of triptans prescribed decreased after starting pro-
pranolol or metoprolol, the decrease is relatively small compared to data from clinical trials.
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Introduction
Migraine is a chronic episodic disorder characterized by
headache attacks accompanied by neurological, gastro-
intestinal and autonomic symptoms (1–3). Patients with
frequent and severe migraine attacks can be prescribed
prophylactic medication to reduce the frequency, dur-
ation, and severity of attacks. Clinical trials on the
prophylactic effect of propranolol and metoprolol
show divergent results concerning the magnitude of
decrease in use of attack medication after starting
these medications. The results from trials range from
a decrease of 0.9 to 8.9 doses/month (4–9) (see online
Appendix 1).
Studies on the effectiveness of this prophylactic
medication in daily practice are needed to get an idea
of the effect of prophylactic medication in daily
practice. However, very few such studies have been
conducted (10). Therefore, it is unclear whether
prophylactic medication in daily practice will lead to
a decrease in the use of attack medication and, if it
does, what the magnitude of its effect is on the use of
attack medication.
This study aims to elucidate whether starting
prophylactic migraine treatment with propranolol or
metoprolol leads to a decrease in the use of attack
medication in daily clinical practice and to determine
the magnitude of the effect.
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We performed a retrospective cohort study in a primary
care population in which we compared triptan prescrip-
tions in the six months before and the six months after
starting prophylactic treatment with propranolol or
metoprolol. These two agents were selected because
these are the most frequently used prophylactic medi-
cations. Also, we decided to focus on triptans as attack
medication because in the Netherlands this medication
is available only by prescription from a physician.
Triptan prescriptions were used as a proxy for use,
because we had no data on actual medication use.
Study population
We retrieved the study population from the electronic
medical records (EMRs) of general practices that par-
ticipated in the NIVEL Primary Care Database, which
is a representative sample of 87 general practices and
approximately 350,000 patients in the Netherlands
(11,12). The NIVEL database is run by the
Netherlands Institute for Health Services Research
(NIVEL) and contains longitudinal data at the patient
level in terms of contacts, morbidity (International
Classification of Primary Care; ICPC) (13)) and
prescriptions. There are small yearly changes in practice
composition. The NIVEL database is registered with
the Dutch Data Protection Authority; data are handled
according to national data protection guidelines
(anonymous patient records and opt-out). In the
Netherlands, this makes ethical approval by an ethics
committee not necessary (14,15).
The patient sample consisted of three cohorts that
were followed for three years, each starting in subse-
quent years: i.e. 2006 (cohort 1), 2007 (cohort 2) and
2008 (cohort 3). We selected patients aged 18 years
who received one or more prescriptions for triptans
available in the Netherlands (almotriptan, eletriptan,
frovatriptan, naratriptan, rizatriptan, sumatriptan, or
zolmitriptan) during the first year (2006, 2007 and
2008, respectively). From these patients we extracted
prescription data of patients for each cohort for three
consecutive years, namely the first year and the two
subsequent years.
Data analyses
Figure 1 presents an overview of the subsequent ana-
lyses. First, for an impression of the natural variation in
the number of triptans prescribed in the entire study
group, we calculated the difference in triptan use
between the first half year and second half year of the
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Figure 1. Flowchart of the composition of the study group and the analyses performed.
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middle year (index year) for all patients with complete
prescription data.
Then, we combined the cohorts and continued with
all patients who started with propranolol or metoprolol
in the second year. We did not use data from patients
who received prescriptions for propranolol 10mg. In
case of missing values in the number of prescriptions,
we used imputation of the mean number of tablets from
other prescriptions. Then, we calculated the mean
number of triptans prescribed per month in the six
months before and the six months after the start of
propranolol or metoprolol, and tested whether the
decrease in the number of triptans prescribed was sig-
nificant. Because the data were paired but not normally
distributed, we used a two-sided Wilcoxon rank test,
with an a priori alpha level 0.05. We performed an add-
itional multilevel Poisson regression analysis to check
for potential confounding by age, sex and general
practice.
We planned three subgroup analyses. Subgroup A
consisted of patients who received prescriptions for
propranolol or metoprolol for at least three consecutive
months. Subgroup B consisted of patients for whom the
propranolol or metoprolol prescription had the ICPC
code migraine (N89) or headache (N01). Subgroup C
was a combination of both (patients who received pro-
pranolol or metoprolol for at least three consecutive
months and a prescription with ICPC code N89 or
N01).
Statistical analyses were performed with the SPSS.
We did not adjust for multiple testing.
Results
We selected 3911 patients (1567 in cohort 1, 1212 in
cohort 2, and 1132 in cohort 3) who received at least
one triptan prescription in the first year. This roughly
corresponds with a percentage of 1% of the total popu-
lation using a triptan out of a total population of
116,489 (cohort 1), 109,331 (cohort 2) and 110,818
(cohort 3) patients.
Investigation of the natural variation in triptans pre-
scribed in 3345 of 3911 patients (86%) with complete
prescription data revealed that the number of triptans
prescribed did not fluctuate between the first and
second half year of our index year. The mean number
of triptans prescribed per month in the first half year
was 2.91 (SD 5.4). In the second half year the number
of triptans prescribed per month increased by 0.05 (SD:
3.5) (difference not significant) (Wilcoxon rank test;
p¼ 0.391).
In total, 168 of 3911 patients (4.3%) received no
prescription for metoprolol or propranolol in the first
year, and at least one prescription for propranolol or
metoprolol in the second year of follow-up (Table 1).
Of all triptan prescriptions, 3% (106 of 3269) did not
include the number of doses. In these cases we used
imputation of the mean number of tablets from other
prescriptions.
In Table 2 we show the change in triptan prescrip-
tions over the course of time. Table 3 shows triptan use
in the six months before and the six months after the
start of propranolol or metoprolol. During the six
months before the start of propranolol/metoprolol the
mean number of triptans prescribed per month was 4.6,
whereas during the six months after the start the mean
number was 3.6. The mean difference in the doses of
triptans prescribed per month between the six months
before and six months after the start of propranolol or
metoprolol was 1.0 triptans per month (Wilcoxon
rank test; p¼ 0.000). This difference was somewhat
larger in subgroup A of patients who received consecu-
tive prescriptions for propranolol or metoprolol for at
least three months, namely 1.3 triptan doses per month.
In subgroup B of patients for whom the propranolol or
metoprolol prescription had the ICPC code for
migraine or headache, the decrease was 0.9 tablets/
month. After combining these two categories (subgroup
C), the difference increased to 1.6 triptan doses per
month.
The multilevel Poisson regression analysis yielded
results similar to the initial analysis, indicating that a
confounding effect of age, sex and general practice was
not present (data not shown).
Discussion
This retrospective cohort study shows that, after start-
ing prophylactic treatment with propranolol or meto-
prolol in daily practice, the number of triptans
prescribed decreased by 1.0 to 1.6 doses per month.
This decrease in triptan use cannot be attributed to
normal fluctuation.
We found a percentage of triptan users in the normal
population of 1.0%, which is comparable to the per-
centage found in an earlier study in a large Dutch pri-
mary care database (15). Also, the number of 168
(4.4%) patients out of 3811 triptan users starting pre-
ventive treatment with propranolol or metoprolol is as
we would expect from earlier research (16).
There are some limitations to this study. We lack
information on actual medication use by patients,
since we had only prescription data from the general
practitioner’s electronic medical record. However, we
assume patients were taking the medication, as the
vast majority received several prescriptions in a row.
Also, a sensitivity analysis spreading the use of triptans
over the period until the next prescription showed no
difference compared with the reported results (see
online Appendix 2). Secondly, we had no data on the
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use of other attack medication (e.g. paracetamol or
nonsteroidal anti-inflammatory drugs (NSAIDs)). Use
of such medications might have concurrently decreased,
or might have increased. However, in the current study,
because triptan use decreased after starting propranolol
or metoprolol, we can assume that migraine attacks
were less frequent and/or severe. Thirdly, we had no
data on prescriptions that patients may have received
from a neurologist. Nevertheless, this is unlikely to
have had a marked effect on our results because in
the Netherlands 95% of triptan prescriptions are
issued by general practitioners (17).
To our knowledge, this is the first study to evaluate
the effect of propranolol and metoprolol on the use of
attack medication in daily practice of primary care.
It appears that starting with propranolol or metoprolol
indeed leads to a decreased use of attack medication.
However, compared with clinical trials this decrease is
lower than expected. This difference is probably par-
tially due to the fact that patients with more frequent
Table 1. Baseline characteristics of the three cohorts of migraine patients who started treatment with propranolol or metoprolol.












Female (%) 81 84 84 83
Age in years 44.8 (12.1) 43.5 (9.2) 44.6 (13.7) 44.4 (12.0)
Number of triptans per months during
the year before starting beta-blocker
(IQR)
4.7 (1.0; 6.7) 4.2 (0.9; 5.5) 4.0 (0.5; 5.0) 4.3 (0.0; 22.5)
Propranolol or metoprolol 3 months
(%)
52 39 57 50
Propranolol or metoprolol continued
until end of period (% of patients
who used propranolol or metoprolol
3 months)
50 59 57 55
Dosage of beta-blockera (%)
Low dosage (propranolol 40 mg or
metoprolol 50 mg per day)
31.1 36.8 23.1 32.1
Middle high dosage (propranolol
80 mg or metoprolol 100 mg per day)
57.4 39.5 46.2 50.0
High dosage (propranolol 160 mg or
metoprolol 200 mg)
4.9 15.8 23.1 10.7
Combination of different dosages 6.6 7.9 7.7 7.1
ICPC coding of indication for pro-
pranolol or metoprolol (%)
N89 (Migraine) 59.7 61.4 38.7 52.4
N01 (Headache) 1.6 2.3 4.8 3.0
K (Circulatory) 24.2 20.5 25.8 23.8
P (Psychological problems) 3.2 4.5 6.5 4.8
IQR: interquartile range; ICPC: International Classification of Primary Care. aData for dosages of beta-blockers known for 66.7% of patients (cohort 1
n¼ 61, cohort 2 n¼ 38 cohort 3 n¼ 13).
Table 2. Number of triptan prescriptions per month. Numbers are means (SD).
Baseline; six
months before start










Total group 4.6 (5.2) 3.9 (6.8) 3.7 (5.1) 3.7 (5.1)
aPatients who continued beta blocker for more than three months.
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and/or severe migraine attacks are recruited for clinical
trials and have more room for improvement. Also, in
our study we could not validly include the use of other
analgesics and NSAIDs (which in the Netherlands are
mainly dispensed over the counter), which might have
concurrently decreased (in our opinion most likely), or
might have increased (least likely). Moreover, bias in
the trials may have played a role as, especially in the
propranolol trials, an intention-to-treat analysis was
not always performed (4). Consequently, these trials
report only on the most compliant patients, a patient
group that is not representative for daily practice. Thus,
clinical trials do not always provide information on the
effect of medication in actual clinical practice.
Therefore, we strongly believe that studies such as the
present one are needed to determine this effect.
Conclusions
We found that during the six months after starting pre-
ventive treatment with propranolol or metoprolol there
was a decrease in the number of triptans prescribed
of 1.0 to 1.6 triptans per month. Hence, we can con-
clude that starting with propranolol or metoprolol in
daily practice indeed leads to a decrease in frequency
and/or severity of migraine attacks. However, com-
pared with data from trials, this decrease is smaller
than expected. This underlines the importance of
studies specifically designed to evaluate the effect
of headache treatment in daily practice.
Clinical implications
. Studies on the prophylactic effect of propranolol and metoprolol on the use of attack medication in daily
practice are lacking.
. In this primary care population, the number of triptans prescribed decreased after starting propranolol or
metoprolol, but the decrease is small compared with data from clinical trials.
. It is important to perform specially designed studies in which the effect of headache treatment is evaluated in
daily practice.
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